PT  - JOURNAL ARTICLE
AU  - Althaus, Karina
AU  - Marini, Irene
AU  - Zlamal, Jan
AU  - Pelzl, Lisann
AU  - Häberle, Helene
AU  - Mehrländer, Martin
AU  - Hammer, Stefanie
AU  - Schulze, Harald
AU  - Bitzer, Michael
AU  - Malek, Nisar
AU  - Rath, Dominik
AU  - Bösmüller, Hans
AU  - Nieswandt, Bernard
AU  - Gawaz, Meinrad
AU  - Bakchoul, Tamam
AU  - Rosenberger, Peter
TI  - Severe COVID-19 infection is associated with increased antibody-mediated platelet apoptosis
AID  - 10.1101/2020.09.03.20187286
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.03.20187286
4099  - http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187286.short
4100  - http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187286.full
AB  - The pathophysiology of COVID-19 associated thrombosis seems to be multifactorial, involving interplay between cellular and plasmatic elements of the hemostasis. We hypothesized that COVID-19 is accompanied by platelet apoptosis with subsequent alteration of the coagulation system. We investigated depolarization of mitochondrial inner transmembrane potential (ΔΨm), cytosolic calcium (Ca2+) concentration, and phosphatidylserine (PS) externalization by flow cytometry. Platelets from intensive care unit (ICU) COVID-19 patients (n=21) showed higher ΔΨm depolarization, cytosolic Ca2+ concentration and PS externalization, compared to healthy controls (n=18) and COVID-19 non-ICU patients (n=4). Moreover significant higher cytosolic Ca2+ concentration and PS was observed compared to septic ICU control group (ICU control). In ICU control group (n=5; ICU non-COVID-19) cytosolic Ca2+ concentration and PS externalization was comparable to healthy control, with an increase ΔΨm depolarization. Sera from ICU COVID-19 13 patients induced significant increase in apoptosis markers (ΔΨm depolarization, cytosolic Ca2+ concentration and PS externalization). compared to healthy volunteer and septic ICU control. Interestingly, immunoglobulin G (IgG) fractions from COVID-19 patients induced an Fc gamma receptor IIA dependent platelet apoptosis (ΔΨm depolarization, cytosolic Ca2+ concentration and PS externalization). Enhanced PS externalization in platelets from ICU COVID-19 patients was associated with increased sequential organ failure assessment (SOFA) score (r=0.5635) and DDimer (r=0.4473). Most importantly, patients with thrombosis had significantly higher PS externalization compared to those without. The strong correlations between apoptosis markers and increased D-Dimer levels as well as the incidence of thrombosis may indicate that antibody-mediated platelet apoptosis potentially contributes to sustained increased thromboembolic risk in ICU COVID-19 patients.Key pointsSevere COVID-19 is associated with increased antibody-mediated platelet apoptosis.Platelet apoptosis in severe COVID-19 is correlated with D-Dimer and higher incidence of thromboembolisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the German Research Foundation and from the Herzstiftung to T.B. (BA5158/4 and TSG-Study), DFG CRC/TR 240 Platelets-Molecular, cellular and systemic functions in health and disease (Project # 374031971) TP A03 (to H.S.), TP B01 (to M.G.), TP B07 (to P.R. and B.N.) and TUEFF-Gleichstellungsfoerderung to K.A. (2563-0-0)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all volunteers prior to any study-related procedure. All tests were performed with rest material from routine testing. The study protocol of patient material was approved by the Institutional Review Board of the University of Tuebingen.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be requested for academic collaboration from the corresponding author.